CLASS ACTION UPDATE for TUP, BDX and ANAB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 1, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

TUP Shareholders Click Here: https://www.zlk.com/pslra-1/tupperware-brands-corporation-loss-form?prid=5872&wire=1
BDX Shareholders Click Here: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=5872&wire=1
ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=5872&wire=1

* ADDITIONAL INFORMATION BELOW *

Tupperware Brands Corporation (NYSE:TUP)

TUP Lawsuit on behalf of: investors who purchased January 30, 2019 – February 24, 2020
Lead Plaintiff Deadline : April 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tupperware-brands-corporation-loss-form?prid=5872&wire=1

According to the filed complaint, during the class period, Tupperware Brands Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Tupperware lacked effective internal controls; (2) as a result, Tupperware would need to investigate the accounting and liabilities of one of its brands, Fuller Mexico; (3) consequently, Tupperware would be unable to timely file its annual report on Form 10-K for its fiscal year 2019; (4) Tupperware did not properly account for its accounts payable and accrued liabilities at Fuller Mexico; (5) Tupperware provided overvalued earnings per share guidance; (6) Tupperware would need relief from its $650 million Credit Agreement; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

Becton Dickinson & Company (NYSE:BDX)

BDX Lawsuit on behalf of: investors who purchased November 5, 2019 – February 5, 2020
Lead Plaintiff Deadline : April 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=5872&wire=1

According to the filed complaint, during the class period, Becton Dickinson & Company made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements;" (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

AnaptysBio, Inc. (NASDAQ:ANAB)

ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline : May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=5872&wire=1

According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 583461